Age and APOE-ε4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP

Synapse

Volumn 60, Issue 1, 2006, Pages 86-92

  Cohen, Robert M ^a,c   Carson, Richard E ^b   Filbey, Francesca ^a   Szczepanik, Joanna ^a   Sunderland, Trey ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Brain imaging; Cholinergic; PET

Indexed keywords

3 [3 [(3 FLUOROPROPYL)THIO] 1,2,5 THIADIAZOL 4 YL] 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; ACETYLCHOLINE; APOLIPOPROTEIN E4; MUSCARINIC M2 RECEPTOR AGONIST; PHYSOSTIGMINE; TRACER; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; FLUORINE; FP TZTP; FP-TZTP; MUSCARINIC M2 RECEPTOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; AGING; ARTICLE; BRAIN; CHOLINERGIC SYSTEM; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; MALE; MEMORY DISORDER; MULTIPLE REGRESSION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL MODEL; TISSUE DISTRIBUTION; AGE; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; AGE FACTORS; AGED; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHYSOSTIGMINE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTOR, MUSCARINIC M2; THIAZOLES;

EID: 33646689528     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20276     Document Type: Article

References (41)

1. Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson AG, Holden PH, Smith SK, Dawbarn D. 1997. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 239:33-36.
2. Bartus RT, Dean RL, Beer C, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
3. Blair JR, Spreen O. 1989. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuopsychol 3:129-136.
4. Bowen DM, Davison AN. 1980. Biochemical changes in the cholinergic system of the ageing brain and in senile dementia. Psychol Med 10:315-319.
5. Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. 1982. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 57: 191-202.
6. Buschke H. 1973. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12:543-550.
7. 18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab 18:1130-1142.
8. Cohen RM, Podruchny TA, Bokde ALW, Carson RE, Herscovitch P, Kiesewetter DO, Eckelman WC, Sunderland T. 2003. Higher in-vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-e4 allele. Synapse 49:150-156.
9. Coyle JT, Price PH, DeLong M. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1189.
10. Davies P, Maloney AFJ. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
11. Davis K, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. 1999. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281:1401-1406.
12. Drachman DA. 1974. Human memory and the cholinergic system. Arch Neurol 30:113-121.
13. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. 1996. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci 802:101-110.
14. Filbey FM, Slack KJ, Kiefer H, Sunderland T, Cohen RM. FMRI and MEG evidence of increased regional activations associated with the APOE-ε4 allele in healthy subjects in their third decade. Presented at the Alzheimer's Association International Conference on Prevention of Dementia, Washington, June 2005 (Abstract No. 63).
15. Flicker C, Ferris S, Serby M. 1992. Hypersensitivity to scopolamine in the elderly. Pyschopharmacology (Berl) 107:437-441.
16. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
17. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
18. Herscovitch P, Markham J, Raichle ME. 1983. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 24:782-789.
19. Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, Rapoport SI, Schapiro MB, Horwitz B. 1998. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50:1585-1593.
20. 18F]FP-TZTP. Nucl Med Biol 30:73-77.
21. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR. 1999. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52:691-699.
22. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
23. 18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid-phase extraction. Nucl Med Biol 30:233-240.
24. Mash DC, Flynn DD, Kalinoski L, Potter LT. 1985. Circadian variations in radioligand binding to muscarine receptors in rat brain dependent upon endogenous agonist occupation. Brain Res 331: 35-38.
25. Mattis S. 1988. DRS: Dementia Rating Scale manual. Odessa, FL: Psychological Assessment Resources.
26. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15: 217-227.
27. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T. 1992. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 17:215-226.
28. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ. 1992. Measurement of radiotracer concentration in brain gray matter using positron emission tomography. MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 12:571-583.
29. Nilsson L, Nordberg A, Hardy P, Wester P, Winblad B. 1986. Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. Neural Trans 67:275-285.
30. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459.
31. Pham DL, Prince JL. 1999. Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imag 18:737-752.
32. Podruchny TA, Connolly C, Bokde A, Herscovitch P, Eckelman WC, Kiesewetter DO, Sunderland T, Carson RE, Cohen RM. 2003. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44.
33. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92:12260-12264.
34. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. 2004. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101:284-289.
35. Riekkinen P, Jr., Soininen H, Partanen J, Paakkonen A, Helisalmi S, Riekkinen P, Sr. 1997. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology (Berl) 129:285-288.
36. Schneider LS, Farlow M. 1997. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. Ann N Y Acad Sci 826:317-322.
37. 18F] fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J Cereb Blood Flow Metab 21:144-148.
38. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S, Ryynanen M, Riekkinen P, Sr. 1995. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurose: Lett 187:79-82.
39. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, III, Murphy DL. 1987. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 44:418-426.
40. Wilcock GK, Esiri MM, Bowen DM, Smith CC. 1982. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57:407-417.
41. Woods R, Mazziotta J, Cherry S. 1993. MRI-PET registration with automated algorithm. J Comp Assist Tomog 17:536-546.